Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


French Competition Body Fines Janssen €25m For Delaying Generic Durogesic

Executive Summary

Janssen-Cilag has been fined €25m by the French competition authority for running a concerted campaign to prevent generic competition to its fentanyl-containing analgesic drug Durogesic. The French medicines regulator does not come out of the affair well either.

You may also be interested in...

Generic smear campaign earns Merck French fine

The French competition authority has fined Merck & Co's Schering-Plough business €15.3m for attempting to block from the market a generic version of its opioid addiction drug Subutex (buprenorphine).

Sanofi fined for smear campaign against generic Plavix

Sanofi has been fined €40.6 million by the French competition authority for abusing a dominant market position to run a smear campaign against generic versions of its blockbuster antithrombotic Plavix (clopidogrel).

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts